Kristen Brown Mini SIM
Pharmacology

Morphine
o Class
 opioid agonists
o Action
 Binds to opiate receptors in the CNS. Alters the perception of and
response to painful stimuli while producing generalized CNS depression
o Therapeutic effect
 Decrease in severity of pain
o Contraindication
 Hypersensitivity
 Some products contain tartrazine, bisulfites, or alcohol and should be
avoided in patients with known hypersensitivity
 Acute, mild, intermittent, or postoperative pain
 Significant respiratory depression
 Acute or severe bronchial asthma
 Paralytic ileus
o Adverse Reaction
 Hypotension, bradycardia
 Flushing, itching, sweating
 Constipation, nausea, vomiting
 Confusion, sedation, dizziness
 Respiratory depression
o Outcomes
 Decrease in severity of pain without a significant alteration in level of
consciousness or respiratory status
 Decrease in symptoms of pulmonary edema

Ondansetron
o Class
 Antiemetic
o Action
 Blocks the effects of serotonin
o Therapeutic effect
 Decreased incidence and severity of nausea and vomiting following
chemotherapy, radiation, or surgery
o Contraindication
 Hypersensitivity
 Orally disintegrating tablets contain aspartame and should not be used in
patients with phenylketonuria
 Congenital long QT syndrome
 Concurrent use of apomorphine
o Adverse Reaction
 Torsades de Pointes (abnormal heart rhythm)
 SJS, topical epidermal necrolysis
 Constipation, diarrhea
o Outcomes
 Prevention of nausea and vomiting associated with emetogenic cancer
chemotherapy.
 Prevention of postoperative nausea and vomiting.
 Prevention of nausea and vomiting due to radiation therapy.